PTPN11 and hepatocellular carcinoma: SHP-2 silencing by siRNA increased the sensitivity of hepatoma cells to sorafenib [105], suggesting that combined use of SHP-2 inhibitor with sorafenib might improve anti-HCC therapeutic efficacy.